GLP-1 agonists are recent additions to the healthcare sector, The US Food and Drug Administration first approved exenatide for type 2 diabetes mellitus in April 2005, subsequently bringing about the authorization of many more GLP-1 agonists [12]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.